vs
Side-by-side financial comparison of Elme Communities (ELME) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
Elme Communities is the larger business by last-quarter revenue ($62.1M vs $38.3M, roughly 1.6× ImmunityBio, Inc.). ImmunityBio, Inc. runs the higher net margin — -161.8% vs -198.9%, a 37.1% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 1.7%). Elme Communities produced more free cash flow last quarter ($7.2M vs $-71.3M).
Elme Communities is a publicly traded U.S. real estate investment trust that primarily owns, operates and develops high-quality multifamily residential communities. It focuses on key growth markets across the U.S. Mid-Atlantic and Southeast, offering affordable to mid-tier housing options for diverse renter groups.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
ELME vs IBRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $38.3M |
| Net Profit | $-123.5M | $-61.9M |
| Gross Margin | 61.1% | 99.0% |
| Operating Margin | -183.3% | -169.0% |
| Net Margin | -198.9% | -161.8% |
| Revenue YoY | 1.7% | 407.0% |
| Net Profit YoY | -4058.7% | -4.7% |
| EPS (diluted) | $-1.40 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $38.3M | ||
| Q3 25 | $62.1M | $32.1M | ||
| Q2 25 | $62.1M | $26.4M | ||
| Q1 25 | $61.5M | $16.5M | ||
| Q4 24 | $61.3M | $7.6M | ||
| Q3 24 | $61.1M | $6.1M | ||
| Q2 24 | $60.1M | — | ||
| Q1 24 | $59.5M | — |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | $-123.5M | $-67.3M | ||
| Q2 25 | $-3.6M | $-92.6M | ||
| Q1 25 | $-4.7M | $-129.6M | ||
| Q4 24 | $-3.0M | $-59.2M | ||
| Q3 24 | $-3.0M | $-85.7M | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $-3.6M | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | 61.1% | 99.4% | ||
| Q2 25 | 63.5% | 99.5% | ||
| Q1 25 | 64.2% | 99.6% | ||
| Q4 24 | 62.9% | — | ||
| Q3 24 | 63.5% | — | ||
| Q2 24 | 63.4% | — | ||
| Q1 24 | 63.5% | — |
| Q4 25 | — | -169.0% | ||
| Q3 25 | -183.3% | -173.5% | ||
| Q2 25 | 9.6% | -269.8% | ||
| Q1 25 | 7.8% | -390.1% | ||
| Q4 24 | 10.4% | -919.0% | ||
| Q3 24 | 11.0% | -1314.3% | ||
| Q2 24 | 9.8% | — | ||
| Q1 24 | 7.5% | — |
| Q4 25 | — | -161.8% | ||
| Q3 25 | -198.9% | -209.8% | ||
| Q2 25 | -5.7% | -350.3% | ||
| Q1 25 | -7.6% | -784.9% | ||
| Q4 24 | -4.9% | -783.4% | ||
| Q3 24 | -4.9% | -1404.0% | ||
| Q2 24 | -5.8% | — | ||
| Q1 24 | -6.1% | — |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-1.40 | $-0.07 | ||
| Q2 25 | $-0.04 | $-0.10 | ||
| Q1 25 | $-0.05 | $-0.15 | ||
| Q4 24 | $-0.04 | $-0.08 | ||
| Q3 24 | $-0.03 | $-0.14 | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $908.9M | $-500.5M |
| Total Assets | $1.7B | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $242.8M | ||
| Q3 25 | $7.1M | $257.8M | ||
| Q2 25 | $4.8M | $153.7M | ||
| Q1 25 | $6.4M | $61.6M | ||
| Q4 24 | $6.1M | $149.8M | ||
| Q3 24 | $4.8M | $130.4M | ||
| Q2 24 | $5.6M | — | ||
| Q1 24 | $4.2M | — |
| Q4 25 | — | $-500.5M | ||
| Q3 25 | $908.9M | $-524.3M | ||
| Q2 25 | $1.0B | $-570.7M | ||
| Q1 25 | $1.1B | $-591.4M | ||
| Q4 24 | $1.1B | $-489.1M | ||
| Q3 24 | $1.1B | $-745.1M | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | — | $501.9M | ||
| Q3 25 | $1.7B | $519.0M | ||
| Q2 25 | $1.8B | $402.1M | ||
| Q1 25 | $1.8B | $303.8M | ||
| Q4 24 | $1.8B | $382.9M | ||
| Q3 24 | $1.9B | $364.6M | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $1.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.9M | $-70.4M |
| Free Cash FlowOCF − Capex | $7.2M | $-71.3M |
| FCF MarginFCF / Revenue | 11.6% | -186.2% |
| Capex IntensityCapex / Revenue | 14.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $86.7M | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-70.4M | ||
| Q3 25 | $15.9M | $-68.9M | ||
| Q2 25 | $29.8M | $-79.7M | ||
| Q1 25 | $16.2M | $-85.9M | ||
| Q4 24 | $95.2M | $-85.1M | ||
| Q3 24 | $20.7M | $-98.8M | ||
| Q2 24 | $28.9M | — | ||
| Q1 24 | $21.2M | — |
| Q4 25 | — | $-71.3M | ||
| Q3 25 | $7.2M | $-69.6M | ||
| Q2 25 | $21.1M | $-80.8M | ||
| Q1 25 | $10.5M | $-87.0M | ||
| Q4 24 | $47.9M | $-87.3M | ||
| Q3 24 | $8.8M | $-101.6M | ||
| Q2 24 | $21.0M | — | ||
| Q1 24 | $7.6M | — |
| Q4 25 | — | -186.2% | ||
| Q3 25 | 11.6% | -217.2% | ||
| Q2 25 | 34.1% | -305.9% | ||
| Q1 25 | 17.1% | -526.9% | ||
| Q4 24 | 78.1% | -1155.4% | ||
| Q3 24 | 14.4% | -1663.2% | ||
| Q2 24 | 34.9% | — | ||
| Q1 24 | 12.8% | — |
| Q4 25 | — | 2.4% | ||
| Q3 25 | 14.0% | 2.3% | ||
| Q2 25 | 14.0% | 4.1% | ||
| Q1 25 | 9.2% | 6.8% | ||
| Q4 24 | 77.4% | 28.0% | ||
| Q3 24 | 19.4% | 45.7% | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | 22.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELME
| Residential Segment | $57.7M | 93% |
| Other | $4.4M | 7% |
IBRX
Segment breakdown not available.
